Navigation Links
Spiral Therapeutics Acquires an Exclusive Option to Develop Two Neuroprotective Agents for the Treatment of Inner Ear Disorders
Date:3/29/2017

SAN FRANCISCO, March 29, 2017 /PRNewswire/ -- Spiral Therapeutics, Inc. today announced the signature of an option agreement with Bionure Farma, S.L. for the worldwide exclusive rights to Bionure's lead candidate, BN201 and to BN119 in the field of otolaryngology for aggregate payments of up to US$4.86 million plus sales-based royalties.

The agreement provides Spiral with the option to license two pre-clinical stage assets with a differentiated product profile. Under the terms of the agreement, Spiral will initiate a feasibility assessment to determine the potential for BN201 and BN119 to be developed for the prevention and treatment of inner ear disorders. Spiral expects to complete this process and to exercise the option by Q3 2017.

"We are very pleased to acquire the opportunity to develop BN201 and BN119 for inner ear disorders and build on Bionure's excellent pre-clinical work around its candidates," said Hugo Peris, founder and CEO of Spiral Therapeutics. "This agreement will accelerate Spiral's vision to become a leading player in the fast-growing inner ear space."

"Spiral has rapidly built strong expertise in the otology field since its foundation last year," said Albert Zamora, CEO of Bionure. "We are pleased to partner with Spiral in progressing our drugs in this important therapeutic area with many unmet medical needs."

About BN201 and BN119

Bionure's compounds BN201 and BN119 are two SGK agonists with remyelinating and neuroprotective activity. Bionure has developed BN201 for the treatment of rare ophthalmic indications associated with multiple sclerosis and expects to receive Clinical Trial Authorization for BN201 in the UK in Q2 2017. BN201 and BN119 could be useful in preventing and treating debilitating inner ear disorders, like sensorineural hearing loss.

About Bionure

Bionure is a late-preclinical drug development company based in Barcelona, Spain focused on developing first-in-class SGK agonists for the treatment of rare ophthalmic diseases. Bionure's lead candidate BN201 is a small molecule, new chemical entity that promotes neuroprotection and remyelination. Bionure plans to start clinical trials in 2017.
www.bionure.com

About Spiral Therapeutics

Spiral Therapeutics is a late stage preclinical company focused on the development of first-in-class products targeting inner ear disorders. Spiral's lead candidate LPT99 for prevention of hearing loss is expected to reach clinical stage in 2018. Spiral is headquartered in San Francisco, CA and has an R&D office in Barcelona, Spain.
www.spiraltx.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/spiral-therapeutics-acquires-an-exclusive-option-to-develop-two-neuroprotective-agents-for-the-treatment-of-inner-ear-disorders-300430547.html


'/>"/>
SOURCE Spiral Therapeutics, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016
2. Akcea Therapeutics Announces Three Additions to Board of Directors
3. Milner Therapeutics Institute Announces New Partnership with Elysium Health
4. ImMAGE Biotherapeutics DNA immunotherapy shows high efficacy with low toxicology results
5. Aprea Therapeutics Announces Research Collaboration with Memorial Sloan Kettering Cancer Center
6. Healthcare Stocks on Investors Radar -- Depomed, Novartis AG, TherapeuticsMD, and Tonix Pharma
7. Pain Therapeutics Attendee List Released Featuring Scientific Leaders and Top Industry Experts
8. PTC Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
9. Patch Pump Drug Delivery Systems Devices Therapeutics Markets Forecasts
10. Lung Therapeutics, Inc. Doses First Patient in Phase 1 Clinical Trial of LTI-01 in Australia and New Zealand
11. Aratana Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2018)... , ... July 20, 2018 ... ... improve one lucky building-industry professional’s summer decking season by giving away a ... cost/labor savings and ease-of-installation of prefabricated railings. Between now and July 25th, ...
(Date:7/22/2018)... Calif. (PRWEB) , ... July 20, 2018 , ... According ... to living a long life lies in the behaviors started as young children. The ... only Blue Zone® to determine their exposure to adverse childhood experiences (ACEs) and the ...
(Date:10/12/2017)... 12, 2017 Providing access to discounted medicine ... commercially insured patients with high deductibles and coinsurance $145 ... new analysis from Milliman that was commissioned by ... data also show sharing negotiated rebates with patients would ... only increase health plan costs on average 1 percent ...
Breaking Medicine Technology:
(Date:7/22/2018)... ... July 20, 2018 , ... A July 10 ... of asking for noses that look like the beautifully proportioned facial appendage sported by ... vogue one for women making similar requests regarding US actress-turned-UK royal Meghan Markle. The ...
(Date:7/22/2018)... ... July 20, 2018 , ... Novant Health is pleased to announce that ... Forsyth Medical Center in Winston-Salem. , Setliff, who begins in the new role on ... Health Kernersville Medical Center and Novant Health Clemmons Medical Center. Before that, he was ...
(Date:7/22/2018)... , ... July 21, 2018 , ... In an upcoming ... in Integrative Medicine. , Integrative Medicine is a type of medicine that considers the ... habits into account. Integrative Medicine is a discipline that hones in on the curative ...
(Date:10/13/2017)... ... 13, 2017 , ... As health professionals work to improve their approach to ... is doing more than filling out a survey; in many cases health professionals and ... in health care and research on the importance of active engagement with patients and ...
(Date:10/13/2017)... , ... October 13, 2017 ... ... of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ... on guideline updates for the primary prevention of cardiovascular diseases during the ...
Breaking Medicine News(10 mins):